89bio's NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference

89bio Inc ETNB announced additional data from its Phase 1b/2a study evaluating BIO89-100 in patients with nonalcoholic steatohepatitis (NASH).

  • The company will present the data at the Endocrine Society's annual meeting.
  • BIO89-100 is a glycoPEGylated analog of FGF21.
  • New analyses showed that BIO89-100 demonstrated clinically meaningful reductions in both liver fat volume and liver volume overall across all dosing groups.
  • Liver volume reduced up to 15%, and liver fat volume decreased to 65% in treated patients at 13 weeks compared to baseline, as measured by magnetic resonance imaging-proton density fat fraction.
  • These data extend the previously reported MRI-PDFF data in which BIO89-100 treatment resulted in up to 70% relative reduction in liver fat fraction relative to placebo treatment.
  • Additionally, BIO89-100, as previously reported, demonstrated a favorable safety and tolerability profile, with rates of gastrointestinal side effects such as nausea, diarrhea, and vomiting similar to placebo.
  • Price Action: ENTB shares were trading 3.8% higher at $26.04 in market trading hours on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralNASHNon Alcoholic steatohepatitisPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!